freeze-thaw cycling comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-05-04. Numbers and descriptions here follow the published literature rather than marketing material.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated or chemically modified byproducts. Mass spectrometry confirms the expected molecular mass and can indicate acetylation state or sequence errors. Amino acid analysis and peptide mapping supply complementary sequence-level information, while endotoxin testing is relevant for preparations intended for cell or animal work. Purity figures reported by suppliers refer to the method used and are not directly comparable across laboratories unless conditions are stated.
Lyophilized material is typically treated as a hygroscopic solid that should be brought to room temperature before the container is opened, which limits condensation on the powder. Reconstitution is commonly done with sterile water or a buffered diluent, and gentle mixing is preferred over vigorous agitation to reduce foaming and surface adsorption. Because peptides can bind to plastic and glass, diluents containing a small amount of carrier protein are sometimes used in laboratory work. Working solutions are generally aliquoted and prepared fresh rather than subjected to repeated freezing and thawing.
Whether the free 28-residue peptide circulates in human tissue remains debated. The best-documented human source is prothymosin alpha, a larger acidic protein that carries the sequence at its N-terminus. Reports of measurable peptide levels in serum and lymphoid tissue exist, yet some of that signal may come from cross-reacting fragments or from the parent protein. Most reviews therefore treat prothymosin alpha as the established human molecule and describe independent circulation of the small peptide as an unresolved question.
Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.
Thymosin alpha-1 is a synthetic 28-amino-acid peptide whose sequence was first identified in extracts of bovine thymus tissue during the 1970s. The chain carries an acetyl group on its N-terminal serine. Its acidic residue content is high, which produces strong water solubility and an isoelectric point well below neutrality. Material supplied for laboratory and clinical use is manufactured by solid-phase peptide synthesis rather than purified from animal tissue. Different salt forms, such as the acetate, alter the counter-ion content without changing the peptide backbone.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white lyophilized powder | Visual description varies by batch |
| Solubility | Freely soluble in water | Aqueous buffers are commonly used |
| Typical storage temperature | -20 °C or below for powder | Reconstituted liquid kept at 2-8 °C short term |
| Purity method | Reversed-phase HPLC | Value derived from peak area integration |
| Identity method | Mass spectrometry | Confirms mass and sequence integrity |
The peptide is generated in cells by cleavage of prothymosin alpha, a larger acidic protein encoded by the PTMA gene. Prothymosin alpha is expressed in many tissues, not only in the thymus, and its functions include nuclear roles in chromatin-related processes. The 28-residue fragment corresponds to the N-terminal portion of that precursor. How the cleavage occurs and how the fragment's concentration is regulated remain open questions; circulating amounts are small and difficult to measure reliably with routine assays.
Thymosin alpha 1 is a short peptide first isolated from bovine thymus tissue in the early 1970s during fractionation work aimed at identifying factors that influence T cell development. It belongs to a family of acidic thymic peptides, and the original preparations contained several components that were later separated by chromatography. The compound is now produced synthetically rather than extracted from tissue, which removes batch variability tied to animal sourcing. Researchers describe it as an immunomodulatory peptide because laboratory studies show effects on several cell types of the innate and adaptive immune systems.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
The peptide was identified during work in the 1970s on thymosin fraction 5, a partially purified extract of calf thymus. Investigators separated that mixture and characterized individual components, one of which they named thymosin alpha-1. The same compound later received the international nonproprietary name thymalfasin. Commercial material is produced by solid-phase peptide synthesis rather than by extraction, so synthetic and natural forms share an identical sequence. Naming conventions vary across the literature, and readers should distinguish the alpha-1 peptide from other thymosins that have unrelated sequences and functions.
Thymosin beta-4 is a separate 43-residue peptide that binds actin and participates in cell migration; it shares no sequence similarity with thymosin alpha-1 despite the common family name. Other preparative materials, such as thymosin fraction 5 and thymopoietin, contain distinct mixtures or peptides. The shared thymosin label reflects the tissue of origin used in early purification, not a common structural core. Treating these molecules as interchangeable is a frequent source of confusion in laboratory reports and in popular summaries alike.
Thymosin alpha-1 is a synthetic peptide of 28 amino acid residues that corresponds to a naturally occurring fragment first isolated from thymus tissue. Its chain is acetylated at the amino terminus, a modification that shields the peptide from rapid cleavage by aminopeptidases. The molecule carries a net negative charge at physiological pH and dissolves freely in water. Researchers classify it as an immune-modulating agent rather than a classical hormone, because it acts on several cell types of both the innate and the adaptive immune system.
The science of blood transfusion dates to the first decade of the 20th century, with the discovery of distinct blood types leading to the practice of mixing some blood from the donor and the receiver before the transfusion (an early form of cross-matching). In the early 19th century, British obstetrician James Blundell made efforts to treat hemorrhage by transfusion of human blood using a syringe. In 1818, after experiments with animals, he performed the first successful transfusion of human blood to treat postpartum hemorrhage at Guy's Hospital in London. Blundell used the patient's husband as a donor, and extracted four ounces of blood from his arm to transfuse into his wife. During the years 1825 and 1830, Blundell performed 10 transfusions, five of which were beneficial, and published his results. He also invented a number of instruments for the transfusion of blood. He made a substantial amount of money from this endeavour, roughly $2 million ($50 million real dollars). In 1840, Samuel Armstrong Lane, aided by Blundell, performed the first successful whole blood transfusion to treat haemophilia at St George's Hospital Medical School in London. However, early transfusions were risky and many resulted in the death of the patient. By the late 19th century, blood transfusion was regarded as a risky and dubious procedure, and was largely shunned by the medical establishment. Work to emulate James Blundell continued in Edinburgh. In 1845 the Edinburgh Journal described the successful transfusion of blood to a woman with severe uterine bleeding.
In the late autumn of 1980, having spent several years on spiritual pursuits and then gradually returning to music (including playing guitar for David Bowie, Brian Eno, Peter Gabriel and Daryl Hall; pursuing an experimental solo career; and leading the instrumental new wave band The League of Gentlemen), Fripp decided to form a new "first division" rock group. Having recruited Bruford as drummer, Fripp then asked the American singer and guitarist Adrian Belew, who had previously played with Bowie and Frank Zappa, to join; this was the first time Fripp would actively seek collaboration with another guitarist in a band, and therefore indicative of his desire to create something unlike any of his previous work. After touring with Talking Heads, Belew agreed to join and also become the band's lyricist. Bruford's suggestion of bassist Jeff Berlin of Bruford was rejected as Fripp thought his playing was "too busy", so auditions were held in New York; on the third day, Fripp left after roughly three auditions, only to return several hours later with session bassist Tony Levin (who got the job after playing a single chorus of "Red"). Fripp later confessed that, had he known that Levin (whom Fripp had played with in Peter Gabriel's group) was available and interested, he would have selected him without holding auditions. Fripp named the new quartet Discipline, and they went to England to rehearse and write new material. They made their live debut at Moles Club in Bath, Somerset on 30 April 1981, and completed a short UK tour supported by the Lounge Lizards.
Tea was first introduced to Western priests and merchants in China during the 16th century, at which time it was termed chá. The earliest European reference to tea, written as chiai, came from Delle navigationi e viaggi written by Venetian Giambattista Ramusio in 1545. The first recorded shipment of tea by a European nation was in 1607 when the Dutch East India Company moved a cargo of tea from Macao to Java, then two years later, the Dutch bought the first assignment of tea which was from Hirado in Japan to be shipped to Europe. Tea became a fashionable drink in The Hague in the Netherlands, and the Dutch introduced the drink to Germany, France, and across the Atlantic to New Amsterdam (New York). In 1567, Russian people came in contact with tea when Cossack leaders (atamans) Petrov and Yalyshev visited China. The Mongolian Khan donated to Tsar Michael I four poods (65–70 kg) of tea in 1638. According to Jeremiah Curtin, it was possibly in 1636 that Vassili Starkov was sent as envoy to the Altyn Khan. He was given 250 pounds of tea as a gift to the tsar. Starkov at first refused, seeing no use for a load of dead leaves, but the Khan insisted. Thus was tea introduced to Russia. In 1679, Russia concluded a treaty on regular tea supplies from China via camel caravan in exchange for furs. It is today considered the de facto national beverage.
=== Artistic use === Synthetic colorants gained popularity as quickly with artists as with industry. The painters of the impressionist school in particular were famous early adopters. Critical reviews of Impressionists’ blues made comparisons to laundresses’ tubs, in particular the practice of laundry bluing, and to chemical waste dumped into the Seine by dye factories. One critic accused Edgar Degas, known for experiments in aquatint, pastel and oil painting as having an obsession with "chemistry," evoking a laboratory in description of his studio. Interestingly, Degas was known to be in correspondence with chemist Marcellin Berthelot, considered the father of organic synthetic chemistry in France. Pierre-Auguste Renoir’s later paintings relied heavily on alizarin crimson. He also employed cobalt blue or a mixture of ultramarine and cobalt blue, a synthetic pigment. New pigments and dyes were not limited to the artists of Europe, even Japanese printmakers were using dyes like rosaniline as early as 1863.
Sources: en.wikipedia.org
=== Mortality === RA reduces lifespan on average from three to twelve years. Young age at onset, long disease duration, the presence of other health problems, and characteristics of severe RA – such as poor functional ability or overall health status, a lot of joint damage on x-rays, the need for hospitalisation or involvement of organs other than the joints – have been shown to associate with higher mortality. Positive responses to treatment may indicate a better prognosis. A 2005 study by the Mayo Clinic noted that individuals with RA have a doubled risk of heart disease, independent of other risk factors such as diabetes, excessive alcohol use, and elevated cholesterol, blood pressure and body mass index. The mechanism by which RA causes this increased risk remains unknown; the presence of chronic inflammation has been proposed as a contributing factor. It is possible that the use of new biologic drug therapies extend the lifespan of people with RA and reduce the risk and progression of atherosclerosis. This is based on cohort and registry studies, and remains hypothetical. It is uncertain whether biologics improve vascular function in RA. There was an increase in total cholesterol and HDLc levels, and no improvement in the atherogenic index.
In bio-informatics, a peptide-mass fingerprint or peptide-mass map is a mass spectrum of a mixture of peptides that comes from a digested protein being analyzed. The mass spectrum serves as a fingerprint in the sense that it is a pattern that can serve to identify the protein. The method for forming a peptide-mass fingerprint, developed in 1993, consists of isolating a protein, breaking it down into individual peptides, and determining the masses of the peptides through some form of mass spectrometry. Once formed, a peptide-mass fingerprint can be used to search in databases for related protein or even genomic sequences, making it a powerful tool for annotation of protein-coding genes. One major advantage to mass fingerprinting is that it is significantly faster to carry out than peptide sequencing, yet the results are equally useful. Disadvantages include the need for a single protein for analysis and the requirement that the protein sequence is located, at least with significant homology, in a database. Because the mass of individual peptides is measured in forming a fingerprint, mixtures of different proteins can yield unreliable results. Therefore, sample preparation is an important step in the process. Even then, if reliable results are obtained, there must be a matching peptide sequence in the database you are searching in order for the results to be useful.
Acanthosis nigricans associated with malignancy (acanthosis nigricans type I) Acanthosis nigricans associated with obesity, insulin-resistant states, and endocrinopathy (acanthosis nigricans type III) Acral acanthosis nigricans (acral acanthotic anomaly) Acral dry gangrene Acromegaly Addison's disease Adrenal adenoma Adrenal carcinoma Adrenal hyperplasia Alopecia–nail dystrophy–ophthalmic complications–thyroid dysfunction–hypohidrosis–ephelides and enteropathy–respiratory tract infections syndrome (ANOTHER syndrome) Arrhenoblastoma Cretinism Cushing's syndrome Excess ovarian androgen release syndrome (ovarian SAHA syndrome) Familial acanthosis nigricans (acanthosis nigricans type II) Growth hormone deficiency Hyperandrogenism–insulin resistance–acanthosis nigricans syndrome (HAIR-AN syndrome) Hyperparathyroidism Hyperprolactinemic SAHA syndrome Hyperthyroidism Hypoparathyroidism Hypothyroidism Leydig cell tumor Multiple endocrine neoplasia type 1 (Wermer syndrome) Multiple endocrine neoplasia type 2 (multiple endocrine neoplasia type 2A, pheochromocytoma and amyloid-producing medullary thyroid carcinoma, PTC syndrome, Sipple syndrome) Multiple endocrine neoplasia type 3 (mucosal neuromata with endocrine tumors, multiple endocrine neoplasia type 2B, multiple mucosal neuroma syndrome, Wagenmann–Froboese syndrome) Myxedema Panhypopituitarism Persistent adrenarche syndrome (adrenal SAHA syndrome) Polycystic ovarian syndrome Seborrhoea–acne–hirsutism–alopecia (SAHA syndrome) Thyroid acropachy
In enzymology, creatinase (EC 3.5.3.3), also known as creatine amidinohydrolase, is classified as a hydrolase enzyme, acting on carbon-nitrogen bonds in linear amidines. Specifically, this enzyme breaks the amidino C-N bond in creatine, producing sarcosine and urea. Creatinase activity has been described in several bacteria species, most notably Pseudomonas putida, where the enzyme plays a key role in the metabolism of creatine as a nitrogen and carbon source.
=== October–December 2007: Participatory notes issue === 18,000, 9 October 2007- The SENSEX crossed the 18,000 mark for the first time on 9 October 2007, gaining 788 points, to close at 18,280. The journey from 17,000 to 18,000 took just 8 trading sessions, which is the third fastest 1000-point rise in the history of the SENSEX. 19,000, 15 October 2007- The SENSEX crossed the 19,000 mark for the first time on 15 October 2007, gaining 640 points, to close at 19,059. It took just 4 trading sessions for the SENSEX to move from 18,000 to 19,000. This is the fastest 1000-point rise ever for the index. In addition, the rise from 16,000 to 19,000 in 17 trading sessions sets a record for the fastest 3,000-point rally in the history of the SENSEX. On 16 October 2007, SEBI (Securities & Exchange Board of India) proposed curbs on participatory notes which accounted for roughly 50% of FII investment in 2007. SEBI was not happy with P-notes because it was not possible to know who owned the underlying securities, and hedge funds acting through P-notes might therefore cause volatility in the Indian markets. However the proposals of SEBI were not clear and this led to a knee-jerk crash when the markets opened on the following day (17 October 2007). Within a minute of opening trade, the SENSEX crashed by 1,744 points or about 9% of its value – the biggest intra-day fall in Indian stock markets in absolute terms until then. This led to the automatic suspension of trade for one hour. Finance Minister P.
Sources: en.wikipedia.org
Cold storage slows the chemical degradation reactions that occur in solution. Lyophilized powder is more stable than reconstituted liquid and tolerates longer storage periods. Repeated temperature cycling should still be avoided because it can drive aggregation and loss of material.
Mass spectrometry is the standard confirmation of molecular mass and acetylation state. Chromatography establishes purity but does not identify the molecule on its own. The two techniques are normally applied together during verification.
No, because the reported value reflects the detection method and wavelength used, which vary between laboratories. A number stated without method details cannot be compared directly with another supplier's figure. Requesting the chromatogram and the method conditions is a common way to interpret it.
It is usually described as an immunomodulatory peptide rather than a classic circulating hormone. No endocrine gland is known to release it as a primary secretory product, and its measured presence in blood is not firmly established.